Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Blair William & Co. IL

Blair William & Co. IL lessened its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 25.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 23,831 shares of the medical equipment provider’s stock after selling 8,202 shares during the period. Blair William & Co. IL’s holdings in Zimmer Biomet were worth $2,174,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Zimmer Biomet by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock valued at $2,609,130,000 after acquiring an additional 166,763 shares during the last quarter. Dodge & Cox lifted its position in shares of Zimmer Biomet by 2.3% during the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock valued at $2,214,305,000 after acquiring an additional 446,018 shares during the last quarter. Ameriprise Financial Inc. lifted its position in shares of Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock valued at $517,039,000 after acquiring an additional 3,208,596 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Zimmer Biomet by 251.3% during the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock valued at $235,571,000 after acquiring an additional 1,488,918 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Zimmer Biomet by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider’s stock valued at $233,009,000 after acquiring an additional 58,060 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $98.34 on Wednesday. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72. The business has a fifty day simple moving average of $101.49 and a 200 day simple moving average of $98.04. The firm has a market cap of $19.48 billion, a price-to-earnings ratio of 23.93, a P/E/G ratio of 2.19 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same period last year, the company earned $2.01 earnings per share. Zimmer Biomet’s quarterly revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Rothschild & Co Redburn assumed coverage on Zimmer Biomet in a report on Thursday, September 18th. They issued a “buy” rating and a $130.00 target price for the company. UBS Group increased their target price on Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a report on Friday, August 8th. Rothschild Redb upgraded Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Finally, Redburn Partners set a $130.00 target price on Zimmer Biomet in a report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $111.94.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.70% of the stock is owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.